National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; WHO Collaborating Centre for Reference and Research on Influenza; Key Laboratory for Medical Virology and Viral Diseases, National Health Commission; National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, Beijing, People's Republic of China.
Emerg Microbes Infect. 2024 Dec;13(1):2373314. doi: 10.1080/22221751.2024.2373314. Epub 2024 Jul 16.
The proportion of human isolates with reduced neuraminidase inhibitors (NAIs) susceptibility in highly pathogenic avian influenza (HPAI) H7N9 virus was high. These drug-resistant strains showed good replication capacity without serious loss of fitness. In the presence of oseltamivir, R229I substitution were found in HA1 region of the HPAI H7N9 virus before NA R292K appeared. HPAI H7N9 or H7N9/PR8 recombinant viruses were developed to study whether HA R229I could increase the fitness of the H7N9 virus bearing NA 292K. Replication efficiency was assessed in MDCK or A549 cells. Neuraminidase enzyme activity and receptor-binding ability were analyzed. Pathogenicity in C57 mice was evaluated. Antigenicity analysis was conducted through a two-way HI test, in which the antiserum was obtained from immunized ferrets. Transcriptomic analysis of MDCK infected with HPAI H7N9 24hpi was done. It turned out that HA R229I substitution from oseltamivir induction in HA1 region increased (1) replication ability in MDCK( < 0.05) and A549( < 0.05), (2) neuraminidase enzyme activity, (3) binding ability to both α2,3 and α2,6 receptor, (4) pathogenicity to mice(more weight loss; shorter mean survival day; viral titer in respiratory tract, < 0.05; Pathological changes in pneumonia), (5) transcriptome response of MDCK, of the H7N9 virus bearing NA 292K. Besides, HA R229I substitution changed the antigenicity of H7N9/PR8 virus (>4-fold difference of HI titre). It indicated that through the fine-tuning of HA-NA balance, R229I increased the fitness and changed the antigenicity of H7N9 virus bearing NA 292K. Public health attention to this mechanism needs to be drawn.
在高致病性禽流感(HPAI)H7N9 病毒中,具有神经氨酸酶抑制剂(NAIs)敏感性降低的人类分离株比例很高。这些耐药株表现出良好的复制能力,而没有严重的适应性损失。在奥司他韦存在的情况下,在 NA R292K 出现之前,在 HPAI H7N9 病毒的 HA1 区域发现了 R229I 取代。为了研究 HA R229I 是否可以提高携带 NA 292K 的 H7N9 病毒的适应性,开发了 HPAI H7N9 或 H7N9/PR8 重组病毒。在 MDCK 或 A549 细胞中评估复制效率。分析神经氨酸酶酶活性和受体结合能力。在 C57 小鼠中评估致病性。通过双向 HI 试验进行抗原性分析,其中抗血清来自免疫的雪貂。对感染 HPAI H7N9 24hpi 的 MDCK 进行转录组分析。结果表明,HA1 区域奥司他韦诱导的 HA R229I 取代增加了(1)MDCK 中的复制能力(<0.05)和 A549(<0.05),(2)神经氨酸酶酶活性,(3)与两种α2,3 和 α2,6 受体的结合能力,(4)对小鼠的致病性(更多体重减轻;平均存活天数更短;呼吸道中的病毒滴度,<0.05;肺炎的病理变化),(5)携带 NA 292K 的 H7N9 病毒的 MDCK 转录组反应。此外,HA R229I 取代改变了 H7N9/PR8 病毒的抗原性(HI 滴度差异超过 4 倍)。这表明,通过精细调整 HA-NA 平衡,R229I 增加了携带 NA 292K 的 H7N9 病毒的适应性,并改变了其抗原性。需要引起公众对这种机制的关注。